PMID- 10942365
OWN - NLM
STAT- MEDLINE
DCOM- 20000907
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 96
IP  - 4
DP  - 2000 Aug 15
TI  - Effect of postremission chemotherapy before human leukocyte antigen-identical 
      sibling transplantation for acute myelogenous leukemia in first complete 
      remission.
PG  - 1254-8
AB  - Allogeneic bone marrow transplantation is an effective postremission strategy for 
      patients with acute myelogenous leukemia (AML) in first complete remission (CR). 
      The value of administering consolidation chemotherapy before human leukocyte 
      antigen (HLA)-identical sibling transplantation is not established. Outcomes of 
      patients with AML in first CR receiving no consolidation therapy, standard-dose 
      cytarabine consolidation therapy, and high-dose cytarabine consolidation therapy 
      before HLA-identical sibling transplantation were compared. Five-year 
      treatment-related mortality rates were 30% (95% confidence interval [CI], 18% to 
      42%) in patients receiving no consolidation chemotherapy, 22% (95% CI, 17% to 
      28%) in those receiving standard-dose cytarabine consolidation, and 24% (95% CI, 
      17% to 31%) in those receiving high-dose cytarabine (P = NS). Five-year 
      cumulative incidences of relapse were 19% (10% to 30%), 21% (16% to 27%), and 17% 
      (11% to 24%), respectively (P = NS). Five-year probabilities of leukemia-free 
      survival were 50% (36% to 63%), 56% (49% to 63%), and 59% (50% to 66%), 
      respectively (P = NS). Five-year probabilities of overall survival were 60% (46% 
      to 71%), 56% (49% to 63%), and 60% (51% to 67%), respectively (P = NS). The data 
      indicate that postremission consolidation with cytarabine before allogeneic 
      transplantation for AML in first CR is not associated with improved outcome 
      compared to proceeding directly to transplantation after successful induction. 
      (Blood. 2000;96:1254-1258)
FAU - Tallman, M S
AU  - Tallman MS
AD  - Acute Leukemia Working Committee of the International Bone Marrow Transplant 
      Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, 
      USA.
FAU - Rowlings, P A
AU  - Rowlings PA
FAU - Milone, G
AU  - Milone G
FAU - Zhang, M J
AU  - Zhang MJ
FAU - Perez, W S
AU  - Perez WS
FAU - Weisdorf, D
AU  - Weisdorf D
FAU - Keating, A
AU  - Keating A
FAU - Gale, R P
AU  - Gale RP
FAU - Geller, R B
AU  - Geller RB
FAU - Laughlin, M J
AU  - Laughlin MJ
FAU - Lazarus, H M
AU  - Lazarus HM
FAU - Luger, S M
AU  - Luger SM
FAU - McCarthy, P L
AU  - McCarthy PL
FAU - Rowe, J M
AU  - Rowe JM
FAU - Saez, R A
AU  - Saez RA
FAU - Vowels, M R
AU  - Vowels MR
FAU - Horowitz, M M
AU  - Horowitz MM
LA  - eng
GR  - P01-CA-40053/CA/NCI NIH HHS/United States
GR  - U24-76518/PHS HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - *Bone Marrow Transplantation
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - HLA Antigens
MH  - Histocompatibility Testing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/pathology/*therapy
MH  - Remission Induction
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2000/08/15 11:00
MHDA- 2000/09/09 11:01
CRDT- 2000/08/15 11:00
PHST- 2000/08/15 11:00 [pubmed]
PHST- 2000/09/09 11:01 [medline]
PHST- 2000/08/15 11:00 [entrez]
AID - S0006-4971(20)71936-1 [pii]
PST - ppublish
SO  - Blood. 2000 Aug 15;96(4):1254-8.